A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...

Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV + CRT ...

Large Language Models in Population Oncology: A Contemporary Review on the Use of Large Language Models to Support Data Collection, Aggregation, and Analysis in Cancer Care and Research This work ...

Dr. Iseult Browne, a clinical research fellow at the ICR and first author of the study, said: “Our study shows that a simple ...

Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA. Among patients with metastatic renal cell carcinoma (mRCC), serial ...

or on the link below. The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in ...

Exclusive: DNA test means patients could be offered most effective treatment first, boosting their chances of beating the disease ...

Circulating tumour DNA (ctDNA) monitoring identified patients with muscle-invasive bladder cancer who showed significantly longer disease-free survival and overall survival when treated with adjuvant ...

Patients found to have positive lymph nodes after robotic radical cystectomy for muscle-invasive bladder cancer may benefit from treatment de-escalation if they have undetectable circulating tumor DNA ...